Market Research Logo

Osteosarcoma - Pipeline Review, H2 2015

Osteosarcoma - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Osteosarcoma - Pipeline Review, H2 2015’, provides an overview of the Osteosarcoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Osteosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteosarcoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Osteosarcoma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Osteosarcoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Osteosarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Osteosarcoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Osteosarcoma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Osteosarcoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Osteosarcoma Overview
Therapeutics Development
Pipeline Products for Osteosarcoma - Overview
Pipeline Products for Osteosarcoma - Comparative Analysis
Osteosarcoma - Therapeutics under Development by Companies
Osteosarcoma - Therapeutics under Investigation by Universities/Institutes
Osteosarcoma - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Osteosarcoma - Products under Development by Companies
Osteosarcoma - Products under Investigation by Universities/Institutes
Osteosarcoma - Companies Involved in Therapeutics Development
Advaxis, Inc.
Amgen Inc.
AVEO Pharmaceuticals, Inc.
Bayer AG
Bellicum Pharmaceuticals, Inc.
Celldex Therapeutics, Inc.
CytRx Corporation
Eleison Pharmaceuticals, Inc.
Exelixis, Inc.
Isofol Medical AB
Merck & Co., Inc.
Merrimack Pharmaceuticals, Inc.
Neusentis
Novartis AG
Oncolys BioPharma Inc.
Shionogi & Co., Ltd.
Sutro Biopharma, Inc.
Teijin Pharma Limited
United Therapeutics Corporation
Osteosarcoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ADXS-HER2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
aldoxorubicin hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AM-7209 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AV-203 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BL-1249 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cabozantinib s-malate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy for GD2 Expressing Solid Tumors - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy to Target HER2 for Glioblastoma Multiforme and Osteosarcoma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
celyvir - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cisplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dinutuximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
everolimus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
glembatumumab vedotin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
irinotecan sucrosofate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ISOMC-091 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LLL-12 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody to Inhibit GD2 for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody to Target Ganglioside GD2 for Neuroblastoma and Osteosarcoma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody to Target GD2 for Osteosarcoma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OBP-702 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pazopanib hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pembrolizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peptide to Target COX-2 and MAS-GPCR for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
radium Ra 223 dichloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RSF-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
S-588410 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Agonize Vitamin D3 Receptor for Osteosarcoma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit CaMKII for Osteosarcoma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaccine for Osteosarcoma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Osteosarcoma - Recent Pipeline Updates
Osteosarcoma - Dormant Projects
Osteosarcoma - Discontinued Products
Osteosarcoma - Product Development Milestones
Featured News & Press Releases
Jul 21, 2015: Advaxis Expands Intellectual Property for Lm Technology Platform in HER2
May 04, 2015: CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers
May 01, 2015: Eleison Announces Successful Completion of Stage 1 of its Phase II Trial of ILC (Inhaled Lipid-complexed Cisplatin) for Pediatric Bone Cancer
Apr 28, 2015: Advaxis Enhances Lm-LLO Cancer Immunotherapy Intellectual Property With USPTO Patent Addressing ADXS-HER2
Nov 04, 2014: Advaxis to Present Data of ADXS-cHER2 at the Society for Immunotherapy of Cancer 29th Annual Meeting
Oct 30, 2014: Advaxis's ADXS-cHER2 Immunotherapy Demonstrates T-Cell Immune Response in Data Analysis From Canine Osteosarcoma Study
Oct 09, 2014: Eleison Announces Completion of Enrollment in Stage 1 of its Phase II Trial of ILC (Inhaled Lipid-complexed Cisplatin) for Pediatric Bone Cancer
May 27, 2014: Advaxis's HER2 Immunotherapy Candidate Receives Orphan Drug Designation for Treatment of Osteosarcoma
Mar 17, 2014: First Cancer Trial Launched Using CAR T Cells Engineered with a Safety Switch
Oct 08, 2013: ILC Granted Orphan Drug Designation in Europe for the Treatment of Osteosarcoma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Osteosarcoma, H2 2015
Number of Products under Development for Osteosarcoma - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd...1)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd...1)
Products under Investigation by Universities/Institutes, H2 2015
Osteosarcoma - Pipeline by Advaxis, Inc., H2 2015
Osteosarcoma - Pipeline by Amgen Inc., H2 2015
Osteosarcoma - Pipeline by AVEO Pharmaceuticals, Inc., H2 2015
Osteosarcoma - Pipeline by Bayer AG, H2 2015
Osteosarcoma - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2015
Osteosarcoma - Pipeline by Celldex Therapeutics, Inc., H2 2015
Osteosarcoma - Pipeline by CytRx Corporation, H2 2015
Osteosarcoma - Pipeline by Eleison Pharmaceuticals, Inc., H2 2015
Osteosarcoma - Pipeline by Exelixis, Inc., H2 2015
Osteosarcoma - Pipeline by Isofol Medical AB, H2 2015
Osteosarcoma - Pipeline by Merck & Co., Inc., H2 2015
Osteosarcoma - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2015
Osteosarcoma - Pipeline by Neusentis, H2 2015
Osteosarcoma - Pipeline by Novartis AG, H2 2015
Osteosarcoma - Pipeline by Oncolys BioPharma Inc., H2 2015
Osteosarcoma - Pipeline by Shionogi & Co., Ltd., H2 2015
Osteosarcoma - Pipeline by Sutro Biopharma, Inc., H2 2015
Osteosarcoma - Pipeline by Teijin Pharma Limited, H2 2015
Osteosarcoma - Pipeline by United Therapeutics Corporation, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Osteosarcoma Therapeutics - Recent Pipeline Updates, H2 2015
Osteosarcoma - Dormant Projects, H2 2015
Osteosarcoma - Dormant Projects (Contd...1), H2 2015
Osteosarcoma - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Osteosarcoma, H2 2015
Number of Products under Development for Osteosarcoma - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report